Inflammation in renal transplantation
- PMID: 19541816
- PMCID: PMC2709521
- DOI: 10.2215/CJN.00930209
Inflammation in renal transplantation
Abstract
Background and objectives: Renal transplant recipients experience premature cardiovascular disease and death. The association of inflammation, all-cause mortality, and cardiovascular events in renal transplant recipients has not been examined in a large prospective controlled trial.
Design, setting, participants, & measurements: ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin on cardiovascular and renal outcomes in 2102 renal transplant recipients. Patients initially randomized to fluvastatin or placebo in the 5- to 6-yr trial were offered open-label fluvastatin in a 2-yr extension to the original study. The association between inflammation markers, high-sensitivity C-reactive protein (hsCRP), and IL-6 on cardiovascular events and all-cause mortality was investigated.
Results: The baseline IL-6 value was 2.9 +/- 1.9 pg/ml (n = 1751) and that of hsCRP was 3.8 +/- 6.7 mg/L (n = 1910). After adjustment for baseline values for established risk factors, the hazard ratios for a major cardiac event and all-cause mortality for IL-6 were 1.08 [95% confidence interval (CI), 1.01 to 1.15, P = 0.018] and 1.11 (95% CI, 1.05 to 1.18, P < 0.001), respectively. The adjusted hazard ratio for hsCRP for a cardiovascular event was 1.10 (95% CI, 1.01 to 1.20, P = 0.027) and for all-cause mortality was 1.15 (95% CI, 1.06 to 1.1.25, P = 0.049).
Conclusions: The inflammation markers IL-6 and hsCRP are independently associated with major cardiovascular events and all-cause mortality in renal transplant recipients.
Figures


Similar articles
-
Inflammatory Markers and Outcomes in Kidney Transplant Recipients.Transplantation. 2017 Sep;101(9):2152-2164. doi: 10.1097/TP.0000000000001548. Transplantation. 2017. PMID: 27798514
-
Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.Nephrol Dial Transplant. 2012 Jun;27(6):2571-5. doi: 10.1093/ndt/gfr694. Epub 2011 Dec 15. Nephrol Dial Transplant. 2012. PMID: 22172725 Clinical Trial.
-
Inflammation-associated graft loss in renal transplant recipients.Nephrol Dial Transplant. 2011 Nov;26(11):3756-61. doi: 10.1093/ndt/gfr163. Epub 2011 Apr 21. Nephrol Dial Transplant. 2011. PMID: 21511816 Clinical Trial.
-
Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients.Clin J Am Soc Nephrol. 2012 Aug;7(8):1257-65. doi: 10.2215/CJN.08410811. Epub 2012 May 24. Clin J Am Soc Nephrol. 2012. PMID: 22626963 Free PMC article.
-
Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.Arthritis Rheum. 2009 Apr;60(4):1060-4. doi: 10.1002/art.24379. Arthritis Rheum. 2009. PMID: 19333947 Clinical Trial.
Cited by
-
Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.Circ Res. 2015 Nov 6;117(11):943-55. doi: 10.1161/CIRCRESAHA.115.306932. Epub 2015 Sep 23. Circ Res. 2015. PMID: 26399469 Free PMC article.
-
Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality.Transplantation. 2013 Nov 15;96(9):807-13. doi: 10.1097/TP.0b013e3182a0f668. Transplantation. 2013. PMID: 23982339 Free PMC article.
-
Potential Health Benefits of Dietary Tree Nut and Peanut Enrichment in Kidney Transplant Recipients-An In-Depth Narrative Review and Considerations for Future Research.Nutrients. 2025 Jul 24;17(15):2419. doi: 10.3390/nu17152419. Nutrients. 2025. PMID: 40806002 Free PMC article. Review.
-
Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study.Transplantation. 2021 May 1;105(5):1106-1115. doi: 10.1097/TP.0000000000003359. Transplantation. 2021. PMID: 32639409 Free PMC article.
-
Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench.Prog Cardiovasc Dis. 2018 Jul-Aug;61(2):168-181. doi: 10.1016/j.pcad.2018.07.001. Epub 2018 Jul 4. Prog Cardiovasc Dis. 2018. PMID: 29981348 Free PMC article. Review.
References
-
- Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024–2031, 2003 - PubMed
-
- Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG: Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 5: 2929–2936, 2005 - PubMed
-
- Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735–1743, 2000 - PubMed
-
- Rigatto C, Parfrey P: Therapy insight: Management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol 2: 514–526, 2006 - PubMed
-
- Kaysen GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 12: 1549–1557, 2001 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials